Tags:
AEterna Zentaris,
AEZS,
anti-cancer compound,
anticancer treatment,
colorectal cancer,
commercialization and licensing agreement,
cost plus basis,
double digit royalties,
Handok,
HIK,
Hikma Pharmaceuticals,
Juergen Engel PhD,
Keryx Biopharmaceuticals,
Mazen Darwazah,
MENA,
Middle East and North Africa,
multiple myeloma,
Nasdaq:AEZS,
NASDAQ:HIK,
NASDAQ:KERX,
oncology drug development company,
oral Akt inhibitor,
perifosine,
PI3K pathway,
Yakult Honsha
Nov 25th, 2011
Tags:
Adult Growth Hormone Deficiency,
AEterna Zentaris,
AEZS,
AEZS-130,
AGHD,
Ardana,
bladder cancer,
cancer,
colorectal,
endometrial,
FDA,
GH threshold level,
GHRH,
growth hormone releasing hormone,
multiple myeloma,
Nasdaq:AEZS,
New Drug Application,
oncology drug development company,
oral diagnostic test,
ovarian,
personalizede medicine,
Phase 3 study,
prostate
Aug 30th, 2011